Experimental infection and protection against ... - TI Pharma
Experimental infection and protection against ... - TI Pharma
Experimental infection and protection against ... - TI Pharma
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
154 Chapter 8<br />
contaminated with bacteria <strong>and</strong> rates of <strong>infection</strong> with frozen <strong>and</strong> thawed SPZ<br />
were highly variable [23-26]. A contemporary approach to production of SPZ for<br />
vaccination requires generating aseptic SPZ-infected mosquitoes, purifying SPZ<br />
from mosquito tissues, vialing, preserving, <strong>and</strong> administering the SPZ by needle<br />
<strong>and</strong> syringe. Sanaria has met these requirements to produce an attenuated<br />
(irradiated) PfSPZ vaccine [27-28] <strong>and</strong> infectious (non-irradiated) aseptic,<br />
purified, vialed, cryopreserved PfSPZ (PfSPZ Challenge). Here we report <strong>infection</strong><br />
of volunteers with PfSPZ Challenge administered intradermally (ID) by needle<br />
<strong>and</strong> syringe.<br />
Methods<br />
Study population <strong>and</strong> study design<br />
This open label, Phase 1 clinical trial was performed at Radboud University<br />
Nijmegen Medical Centre, the Netherl<strong>and</strong>s, from October 2010 to July 2011.<br />
Volunteers aged 18-35 years were screened for eligibility by assessing medical<br />
history, physical examination, haematological, biochemical, urine toxicology, <strong>and</strong><br />
pregnancy tests, <strong>and</strong> malaria, HIV, hepatitis B <strong>and</strong> hepatitis C serology. The main<br />
exclusion criteria were pregnancy, residence in a malaria endemic area within<br />
the previous six months, positive Pf serology, symptoms, physical signs or<br />
laboratory test results suggestive of systemic disorders, <strong>and</strong> history of drug or<br />
alcohol abuse interfering with normal social function. All volunteers gave written<br />
informed consent.<br />
Eighteen healthy malaria-naïve volunteers were recruited for this trial. Groups of<br />
six volunteers were injected ID with 2,500, 10,000, or 25,000 PfSPZ Challenge.<br />
The sample size of six per group had a power of 75% to show a difference<br />
between 2 of 6 volunteers infected in the 2,500 PfSPZ group <strong>and</strong> 6/6 volunteers<br />
infected in the 25,000 PfSPZ group. Dose escalation was done at a minimum<br />
interval of 3.5 weeks.<br />
The trial was performed in accordance with Good Clinical Practice <strong>and</strong> an<br />
Investigational New Drug application filed with the U.S. Food <strong>and</strong> Drug<br />
Administration, <strong>and</strong> approved by the Central Committee for Research Involving<br />
Human Subjects of The Netherl<strong>and</strong>s (CCMO NL31858.091.10). Clinicaltrials.gov<br />
identifier: NCT 01086917.